Article
Patient satisfaction and experience with intravenously administered C1-inhibitor concentrates in the United States.
Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology - 1 Jul 2017
Riedl Marc A, Banerji Aleena, Busse Paula J, Johnston Douglas T, Davis-Lorton Mark A, Patel Shital, Parr Howard, Chiao Joseph, Watson Douglas J, Burrell Earl, Machnig Thomas
Abstract excerpt
BACKGROUND: Hereditary angioedema (HAE) is a rare genetic disorder with substantial morbidity and mortality. Despite expanded choices for effective acute treatment, prophylactic options are more limited. Intravenous C1 esterase inhibitor (C1-INH[IV]) is licensed and used to prevent HAE symptoms. OBJECTIVE: To better understand patient experiences with using C1-INH(IV), including level of satisfaction and types...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.